Zimmer Biomet stock forecast 2027–2029
MyStockButler's October 2026 analysis: Zimmer Biomet's weighted path reaches $139.22 by October 2029, a total return of 44% including dividends. It hinges on whether Zimmer Biomet converts technology and coverage into procedures while improving cash returns.
Where could Zimmer Biomet's shares be by October 2029?
The weighted path reaches $113.38 by October 2027 and $125.53 by October 2028. By October 2029 it reaches $139.22, a total return of 44% including dividends. The first two total returns are 16% and 29%.
At the final date, the bear outcome is $76.19 and the bull outcome is $234.47. Today’s price is $98.56. The base case carries 57% probability. Bear and bull carry 28% and 15%.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 28 % | 88.64 (-9 %) | 79.95 (-17 %) | 76.19 (-20 %) |
| Base | 57 % | 116.46 (+19 %) | 130.57 (+34 %) | 145.12 (+50 %) |
| Bull | 15 % | 147.86 (+51 %) | 191.47 (+96 %) | 234.47 (+141 %) |
| Weighted | 100 % | 113.38 (+16 %) | 125.53 (+29 %) | 139.22 (+44 %) |
What has to go right, and what could go wrong for Zimmer Biomet?
The base assumes modest revenue growth and gradual margin recovery as restructuring savings offset sales-transition costs. The bear keeps pricing, knee-share pressure and coverage problems strong enough to erode margins. The bull assumes new products, ROSA utilization and Paragon expansion produce profitable incremental cases. Revenue grew 7.2% in 2025, but adjusted earnings were nearly flat, so the base favors improvement without a rapid rebound.
How much cash does Zimmer Biomet really make?
A stricter measure deducts stock-based compensation from free cash flow. That charge represents paying employees with ownership in the company, so it is an economic cost even though it is not a second cash payment. Free cash flow also remains before acquisitions and other investing outlays.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 1,697.1 | 1,499.4 | 1,581.6 | 1,356.2 | 1,404.3 |
| − Capital spending | 525.0 | 444.1 | 602.8 | 446.2 | 417.2 |
| = Free cash flow | 1,172.1 | 1,055.3 | 978.8 | 910.0 | 987.1 |
| − Stock pay | 90.2 | 101.0 | 99.8 | 105.0 | 76.0 |
| = Real free cash flow | 1,081.9 | 954.3 | 879.0 | 805.0 | 911.1 |
| Real free cash flow, % of revenue | 13.1% | 12.4% | 11.9% | 11.6% | 13.3% |
What this means. The company's own free cash flow is higher because it does not subtract shares given to employees as pay; we subtract them because they give away part of the company.
What does an investor pay today for Zimmer Biomet?
Cash flow provides a stricter test. Zimmer Biomet often places implants and instruments at a hospital on consignment: it owns the implant until a surgeon uses it, then invoices the hospital. Profit can therefore arrive before cash, while inventory and equipment absorb funding. The stock offers a 6.2% free cash flow yield and a 5.8% “real” free cash flow yield, but neither is a promised payment. Dividends yield 1.0%, while a $1.5 billion buyback authorization competes with debt repayment and refinancing.
| Today (Oct 23, 2026) | |
|---|---|
| Share price | 98.56 |
| Market value (calculated) | 18,799.1 |
| Enterprise value (calculated) | 25,868.1 |
| P/E, last 12 months (calculated) | 24.0x |
| P/E, next 12 months (calculated) | 10.9x |
| Real free cash flow yield (calculated) | 5.8% |
What this means. The lower price-to-earnings number for the next year uses analysts’ expected profits, so it is only an estimate and may be wrong.